{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:07:03Z","timestamp":1776722823366,"version":"3.51.2"},"reference-count":18,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>X-linked hypophosphatemia (XLH), a rare genetic disorder caused by PHEX mutations, leads to fibroblast growth factor 23\u2013mediated phosphate wasting, hypophosphatemia, and impaired bone mineralization. We report a 28-year-old woman with XLH carrying a heterozygous PHEX c.1080-1G&amp;gt;A splice-site mutation and a CLDN16 c.165_166delinsC mutation. Diagnosed at 18 months of age, she received long-term phosphate and active vitamin D metabolites, which resulted in secondary hyperparathyroidism, vertebral fractures, and medullary nephrocalcinosis requiring subtotal parathyroidectomy. Although CLDN16 mutation carriers are usually asymptomatic, coexistence of XLH and prolonged phosphate therapy may exacerbate renal magnesium and calcium handling defects, potentially contributing to nephrocalcinosis. Burosumab was initiated for ongoing complications. Before surgery, she was wheelchair dependent due to severe diffuse bone pain. Postoperatively, pain improved and she regained independent ambulation, which further improved after burosumab initiation. Laboratory findings showed partial but sustained improvements in serum phosphate, alkaline phosphatase, and parathyroid hormone levels. Incomplete biochemical normalization may reflect renal tubular acidosis and medullary calcinosis. This case suggests long-term phosphate therapy can adversely affect parathyroid glands and may exacerbate nephrocalcinosis in the presence of tubular vulnerabilities. It supports burosumab as an effective therapeutic option in patients with coexisting renal tubular disorders.<\/jats:p>","DOI":"10.1210\/jcemcr\/luag043","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T02:44:37Z","timestamp":1774320277000},"source":"Crossref","is-referenced-by-count":1,"title":["X-linked hypophosphatemia in the presence of a\n                    <i>CLDN16<\/i>\n                    variant: implications for renal handling and disease severity"],"prefix":"10.1210","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1634-1865","authenticated-orcid":false,"given":"Seol A","family":"Jang","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine , Yongin 16995 ,","place":["South Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8150-0266","authenticated-orcid":false,"given":"Kyoung Min","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine , Yongin 16995 ,","place":["South Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4227-5638","authenticated-orcid":false,"given":"Yumie","family":"Rhee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institute of Endocrine Research, Severance Hospital, Yonsei University College of Medicine , Seoul 03722 ,","place":["South Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"issue":"6","key":"2026032322443015600_luag043-B1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41574-022-00662-x","article-title":"Interdisciplinary management of FGF23-related phosphate wasting syndromes: a consensus statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia","volume":"18","author":"Trombetti","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"11-12","key":"2026032322443015600_luag043-B2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1515\/jpem-2014-0447","article-title":"Risk factors affecting the development of nephrocalcinosis, the most common complication of hypophosphatemic rickets","volume":"28","author":"Keskin","year":"2015","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"8","key":"2026032322443015600_luag043-B3","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1210\/clinem\/dgaf170","article-title":"X-linked hypophosphatemia management in adults: an international working group clinical practice guideline","volume":"110","author":"Khan","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026032322443015600_luag043-B4","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"21","key":"2026032322443015600_luag043-B5","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"2026032322443015600_luag043-B6","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1007\/s00467-021-04968-2","article-title":"Familial hypomagnesemia with hypercalciuria and nephrocalcinosis","volume":"36","author":"Vall-Palomar","year":"2021","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"2026032322443015600_luag043-B7","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1172\/JCI26323","article-title":"Disease-associated mutations affect intracellular traffic and paracellular Mg2 + transport function of Claudin-16","volume":"116","author":"Kausalya","year":"2006","journal-title":"J Clin Invest"},{"key":"2026032322443015600_luag043-B8","doi-asserted-by":"crossref","first-page":"1229750","DOI":"10.3389\/fendo.2023.1229750","article-title":"Elevated morbidity and mortality in patients with chronic idiopathic hypophosphatemia: a nationwide cohort study","volume":"14","author":"Kim","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2026032322443015600_luag043-B9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3177\/jnsv.60.140","article-title":"Oral phosphorus supplementation secondarily increases circulating fibroblast growth factor 23 levels at least partially via stimulation of parathyroid hormone secretion","volume":"60","author":"Takasugi","year":"2014","journal-title":"J Nutr Sci Vitaminol (Tokyo)"},{"issue":"2","key":"2026032322443015600_luag043-B10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/EJE-15-0515","article-title":"Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications","volume":"174","author":"Rafaelsen","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026032322443015600_luag043-B11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00223-023-01172-2","article-title":"Disease manifestations and complications in Dutch X-linked hypophosphatemia patients","volume":"114","author":"Bosman","year":"2024","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"2026032322443015600_luag043-B12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12882-015-0079-4","article-title":"Identification of the first large deletion in the CLDN16 gene in a patient with FHHNC and late-onset of chronic kidney disease: case report","volume":"16","author":"Yamaguti","year":"2015","journal-title":"BMC Nephrol"},{"issue":"12","key":"2026032322443015600_luag043-B13","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1007\/s40618-025-02678-2","article-title":"The genetic polymorphism of XPR1 associated with Fanconi syndrome in Chinese patients with X-linked hypophosphatemia","volume":"48","author":"Han","year":"2025","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2026032322443015600_luag043-B14","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s41581-024-00926-x","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"21","author":"Haffner","year":"2025","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"2026032322443015600_luag043-B15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/archdischild-2022-324962","article-title":"Burosumab in management of X-linked hypophosphataemia: a retrospective cohort study of growth and serum phosphate levels","volume":"108","author":"Walker","year":"2023","journal-title":"Arch Dis Child"},{"key":"2026032322443015600_luag043-B16","doi-asserted-by":"crossref","first-page":"1487890","DOI":"10.3389\/fped.2024.1487890","article-title":"Nephrocalcinosis tendency does not worsen under burosumab treatment for X-linked hypophosphatemic rickets: a multicenter pediatric study","volume":"12","author":"Levi","year":"2024","journal-title":"Front Pediatr"},{"issue":"6","key":"2026032322443015600_luag043-B17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1515\/jpem-2020-0734","article-title":"Switching from conventional therapy to burosumab injection has the potential to prevent nephrocalcinosis in patients with X-linked hypophosphatemic rickets","volume":"34","author":"Harada","year":"2021","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"3","key":"2026032322443015600_luag043-B18","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00467-022-05636-9","article-title":"X-linked hypophosphatemia, obesity and arterial hypertension: data from the XLH21 study","volume":"38","author":"Bloudeau","year":"2023","journal-title":"Pediatr Nephrol"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/4\/luag043\/67486055\/luag043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/4\/luag043\/67486055\/luag043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T02:44:40Z","timestamp":1774320280000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luag043\/8538014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,19]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luag043","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,3,19]]},"article-number":"luag043"}}